• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon

Phenotypic Disease Modeling for Immuno-Oncology: Putting Targets into Patient Context

On-demand Webinar

Modeling cancer with precision and accuracy requires the analysis of tumor modalities such as growth patterns, stromal shielding, vascularization, inflammation, mesenchymal transition, and metastasis. Organ-on-a-chip technology, such as the OrganoPlate® platform, may recapitulate the tumor microenvironment (TME) in vitro, offering unparalleled detail and human relevance in a 3D environment. Developing complex in vitro cancer models, that closely mimic this multi-faceted disease, is pivotal in improving cancer drug discovery and establishing more effective treatments for patients.

Novel and recently approved drugs, such as T-cell engagers and checkpoint inhibitors, indicate the principal role of the immune system in cancer. Teasing apart the intricate and dynamic interactions between cancer cells, immune cells and the surrounding tumor tissue is a critical step in gaining a better understanding of the immune system’s role in the disease.

Watch our on-demand webinar with Henriëtte Lanz, PhD (Vice President Biology at MIMETAS). Dive deep into MIMETAS’ expertise in disease modeling and drug screening within the field of immuno-oncology. The webinar explores, among other topics, the immuno-suppressive and stimulatory nature of the tumor microenvironment (TME) in hepatocellular carcinoma.

Key topics include:


  • Comprehensive in vitro modeling of the TME
  • The interplay between angiogenesis, stroma and immune infiltrate
  • The influence of different parameters of the TME on the response to Standard of Care
  • The benefits of partnering with MIMETAS to accelerate your research and improve predictive responses to conventional and targeted therapies


Access the recording here




Henriette Lanz, PhD is Vice President Biology at MIMETAS. She studied Life, Science and Technology during both her bachelor and master degrees, before conducting her PhD research on cancer-related targets sensed by apoptin, a tumor-selective apoptosis inducing protein, at Leiden University. At MIMETAS, she oversees the Model Development Department, being part of various types of internal and external projects.






May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all